BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Leyfman Y, Erick TK, Reddy SS, Galwankar S, Nanayakkara PWB, Di Somma S, Sharma P, Stawicki SP, Chaudry IH. Potential Immunotherapeutic Targets for Hypoxia Due to COVI-Flu. Shock 2020;54:438-50. [PMID: 32649367 DOI: 10.1097/SHK.0000000000001627] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Hosseini P, Fallahi MS, Erabi G, Pakdin M, Zarezadeh SM, Faridzadeh A, Entezari S, Ansari A, Poudineh M, Deravi N. Multisystem Inflammatory Syndrome and Autoimmune Diseases Following COVID-19: Molecular Mechanisms and Therapeutic Opportunities. Front Mol Biosci 2022;9:804109. [DOI: 10.3389/fmolb.2022.804109] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Snell-Rood EC, Smirnoff D, Cantrell H, Chapman K, Kirscht E, Stretch E. Bioinspiration as a method of problem-based STEM education: A case study with a class structured around the COVID-19 crisis. Ecol Evol 2021. [PMID: 34900221 DOI: 10.1002/ece3.8044] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Dobson GP, Biros E, Letson HL, Morris JL. Living in a Hostile World: Inflammation, New Drug Development, and Coronavirus. Front Immunol 2020;11:610131. [PMID: 33552070 DOI: 10.3389/fimmu.2020.610131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
4 Papadimos TJ, Soghoian SE, Nanayakkara P, Singh S, Miller AC, Saddikuti V, Jayatilleke AU, Dubhashi SP, Firstenberg MS, Dutta V, Chauhan V, Sharma P, Galwankar SC, Garg M, Taylor N, Stawicki SP. COVID-19 Blind Spots: A Consensus Statement on the Importance of Competent Political Leadership and the Need for Public Health Cognizance. J Glob Infect Dis 2020;12:167-90. [PMID: 33888955 DOI: 10.4103/jgid.jgid_397_20] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
5 Downing S, Chauhan V, Chaudry IH, Galwankar S, Sharma P, Stawicki SP. Colchicine, Aspirin, and Montelukast - A Case of Successful Combined Pharmacotherapy for Adult Multisystem Inflammatory Syndrome in COVID-19. J Glob Infect Dis 2020;12:221-4. [PMID: 33888963 DOI: 10.4103/jgid.jgid_296_20] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
6 Zhou L, Huntington K, Zhang S, Carlsen L, So EY, Parker C, Sahin I, Safran H, Kamle S, Lee CM, Geun Lee C, A Elias J, S Campbell K, T Naik M, J Atwood W, Youssef E, A Pachter J, Navaraj A, A Seyhan A, Liang O, El-Deiry WS. MEK inhibitors reduce cellular expression of ACE2, pERK, pRb while stimulating NK-mediated cytotoxicity and attenuating inflammatory cytokines relevant to SARS-CoV-2 infection. Oncotarget 2020;11:4201-23. [PMID: 33245731 DOI: 10.18632/oncotarget.27799] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
7 Chiang N, Serhan CN. Specialized pro-resolving mediator network: an update on production and actions. Essays Biochem 2020;64:443-62. [PMID: 32885825 DOI: 10.1042/EBC20200018] [Cited by in Crossref: 27] [Cited by in F6Publishing: 87] [Article Influence: 13.5] [Reference Citation Analysis]